Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access

Prior treatment

• Diabetic ketoacidosis (DKA) in previous 6 months

Other illness

• End-Stage Renal Disease (ESRD)

Other

• Insulin naïve
• Contraindications to CGM use
• Active insurance plan that would provide enough of a subsidy for participant to feasibly purchase CGM sensors
• Pregnancy

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Diagnosed with type 2 diabetes mellitus
• A1c greater than or equal to 8.0 within two weeks of the time of enrollment
• On insulin for at least one year +/- other antihyperglycemics
• Ability and willingness to wear CGM for 14-day periods throughout the trial period
• Ability and willingness to comply with provider-directed adjustments to medication regimen
• Inability to afford CGM sensors
  • A note on Vulnerable Populations: Many of FHCHC's patients are economically disadvantaged and of minority backgrounds; the clinic's patient base may be considered to constitute a vulnerable population. As such, recruitment and enrollment will be conducted within a vulnerable population. The nature of the study requires this, and the results are intended to directly benefit this population through the potential for improved glycemic control and quality of life.